Apologies for any confusion caused. Here is the revised response without any unnecessary phrase:
Tempest Therapeutics, Inc. (Nasdaq: TPST) has announced that it has granted nonqualified stock options to two employees under its 2023 Inducement Plan. The options allow the employees to purchase a total of 45,500 shares of the company’s common stock. The stock options will vest over a four-year period, with a portion of the options vesting on each anniversary of the employee’s start date, subject to continued employment.
